Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harriet O Smith

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
American Journal of Clinical Oncology|November 4, 2009
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancerHouman M Fekrazad, Claire F Verschraegen, Melanie Royce, et al.
Gynecologic Oncology|January 4, 2011
Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysisJune Hou, Gary L Goldberg, Clifford R Qualls, et al.
Gynecologic Oncology|January 24, 2006
Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003)Gary L Goldberg, Paniti Sukumvanich, Mark H Einstein, et al.
Obstetrics and Gynecology|May 2, 2006
Incidence and survival rates for female malignant germ cell tumorsHarriet O Smith, Marianne Berwick, Claire F Verschraegen, et al.
Annual Review of Physiology|February 15, 2008
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30Eric R Prossnitz, Jeffrey B Arterburn, Harriet O Smith, et al.
Obstetrics and Gynecology|December 16, 2003
Trends in gestational choriocarcinoma: a 27-year perspectiveHarriet O Smith, Clifford R Qualls, Beth A Prairie, et al.
Oncology|February 5, 2010
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group StudyAmy D Tiersten, James Moon, Harriet O Smith, et al.
The Journal of Reproductive Medicine|November 8, 2006
Changing trends in gestational trophoblastic diseaseHarriet O Smith, Charles Wiggins, Claire F Verschraegen, et al.
American Journal of Obstetrics and Gynecology|April 4, 2007
GPR30: a novel indicator of poor survival for endometrial carcinomaHarriet O Smith, Kimberly K Leslie, Meenakshi Singh, et al.
Gynecologic Oncology|January 14, 2009
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009Amy D Tiersten, P Y Liu, Harriet O Smith, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Oncology|November 4, 2009
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancerHouman M Fekrazad, Claire F Verschraegen, Melanie Royce, et al.
Gynecologic Oncology|January 4, 2011
Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysisJune Hou, Gary L Goldberg, Clifford R Qualls, et al.
Gynecologic Oncology|January 24, 2006
Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003)Gary L Goldberg, Paniti Sukumvanich, Mark H Einstein, et al.
Obstetrics and Gynecology|May 2, 2006
Incidence and survival rates for female malignant germ cell tumorsHarriet O Smith, Marianne Berwick, Claire F Verschraegen, et al.
Annual Review of Physiology|February 15, 2008
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30Eric R Prossnitz, Jeffrey B Arterburn, Harriet O Smith, et al.
Obstetrics and Gynecology|December 16, 2003
Trends in gestational choriocarcinoma: a 27-year perspectiveHarriet O Smith, Clifford R Qualls, Beth A Prairie, et al.
Oncology|February 5, 2010
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group StudyAmy D Tiersten, James Moon, Harriet O Smith, et al.
The Journal of Reproductive Medicine|November 8, 2006
Changing trends in gestational trophoblastic diseaseHarriet O Smith, Charles Wiggins, Claire F Verschraegen, et al.
American Journal of Obstetrics and Gynecology|April 4, 2007
GPR30: a novel indicator of poor survival for endometrial carcinomaHarriet O Smith, Kimberly K Leslie, Meenakshi Singh, et al.
Gynecologic Oncology|January 14, 2009
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009Amy D Tiersten, P Y Liu, Harriet O Smith, et al.
Pageof 4